FDA Approves Enhertu for Two New HER2-Positive Early Breast Cancer Indications
FDA & EMA
FDA Approves Sonrotoclax as First BCL2 Inhibitor for R/R Mantle Cell Lymphoma
Perioperative Durvalumab Regimen Improves EFS and OS in Muscle-Invasive Bladder Cancer
Clinical Trials
FDA Approves First All-Oral INQOVI Plus Venetoclax Regimen for Newly Diagnosed AML
FDA Grants RMAT Designation to RZ-001, a Novel RNA Therapy for Hepatocellular Carcinoma
FDA Approves Bizengri as First Targeted Therapy for NRG1 Fusion+ Cholangiocarcinoma
FDA Grants Fast Track Designation to RPTR-1-201 for Advanced Triple- Breast Cancer
PHERGain Data Support Chemo-Free Treatment With 90% Five-Year RFS in Breast Cancer
ONCOLife
FDA Grants Fast Track Designation to Dubodencel for Advanced Cutaneous Melanoma
Targeting RNase H2 Exposes a New Therapeutic Vulnerability in Triple-Negative Breast Cancer
FDA Accepts IBTROZI sNDA After Durable Long-Term Benefit in Advanced ROS1+ Lung Cancer
ALK Mutation Emerges as a Potential Biomarker for Pan-Cancer Immunotherapy Benefit
FDA ODAC Backs Truqap Combination for PTEN-Deficient Metastatic Prostate Cancer
Misinformation Drives Over 16 Million Americans Toward High Skin Cancer Risk
Zeta Navigation System Gains FDA Clearance for Brain Tumor Biopsy and Neurosurgery
FDA Approves Vepdegestrant, First PROTAC Therapy for ESR1+ ER+/HER2- Breast Cancer
SUNRISE-II Trial Begins Evaluating Ultrasound-Guided HIFU Ablation for Pancreatic Cancer
Restoring Proteostasis May Boost T Cell Function and Open a New Route for Immunotherapy
OPTIMAL Data Support TLX597-Tx as a Next-Gen Radioligand Therapy in Prostate Cancer
AidaBREAST Gains FDA Breakthrough Status for Personalized Radiotherapy in Breast Cancer
Phase 3 MagnetisMM-5 Trial Supports Earlier Use of Elranatamab in Relapsed Myeloma
Real-World Analysis Links Community Oncology Care to Longer Survival in Multi-Cancer
Dual Pathway Blockade Achieves 40% Response in Clear Cell Gynaecological Cancer
Early CAR T-Cell Intervention Shows Disease-Eradication Potential in High-Risk Myeloma
World’s First Nectin-4-Targeting ADC Enters Phase III Trial in Triple-Negative Breast Cancer
Long-Term Data Show Taletrectinib Delivers High Response Rates in ROS1+ NSCLC
FDA-Cleared Utepreva Device Aims to Improve Early Endometrial Cancer Detection
Cancer
Opaganib Shows Dual Preclinical Promise in Neuroblastoma and Triple- Breast Cancer
Ozekibart Shows Encouraging Late-Line Activity in Metastatic Colorectal Cancer
FDA Grants Breakthrough Status to First Viral Liquid Biopsy in Hepatocellular Carcinoma
Subscribe for the latest news and events
Most Popular
Improving Everolimus Safety in Oncology: Missed Opportunities in Risk Minimization
Targeting the ‘Don’t Eat Me’ Signal: The Future of Macrophage Checkpoint Inhibitors
FDA Approves Wegovy to Reduce Risk of Heart Problems in Obese Adults
A New Era in Liver Disease: FDA Approves First Medication 'Rezdiffra' for NASH
Zongertinib Gains FDA Accelerated Approval for HER2+ NSCLC with 75% ORR
Exploring the Transformative Power of AI in Drug Discovery: A report by S&P Global
NETTER-2 Trial: Lutathera Cuts Risk of Death by 72% in Neuroendocrine Tumor Treatment
EpCAM-Targeting ADC CX-2051 Shows Promising Efficacy in Advanced Colorectal Cancer
FDA Grants Accelerated Approval to Semaglutide for MASH with Liver Fibrosis
Bayer Poised for Landmark Year with Blockbuster Treatment Advances Across Key Diseases
Transformative One-Time Gene Therapy: FDA Approves Pfizer's BEQVEZ, for Hemophilia B
NEJM Study Confirms Low-Dose Aspirin Halves Recurrence in Colorectal Cancer
FDA Approves Groundbreaking CAR T Cell Therapy, Abecma, for Multiple Myeloma
New Horizon in Food Allergy Treatment: FDA Approves Xolair for All Ages
FDA Approves Carvykti as Targeted CAR-T Cell Therapy for Multiple Myeloma
